These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17142049)

  • 1. Transformation of mu-opioid receptor agonists into biologically potent mu-opioid receptor antagonists.
    Li T; Jinsmaa Y; Nedachi M; Miyazaki A; Tsuda Y; Ambo A; Sasaki Y; Bryant SD; Marczak E; Li Q; Swartzwelder HS; Lazarus LH; Okada Y
    Bioorg Med Chem; 2007 Feb; 15(3):1237-51. PubMed ID: 17142049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties.
    Balboni G; Guerrini R; Salvadori S; Bianchi C; Rizzi D; Bryant SD; Lazarus LH
    J Med Chem; 2002 Jan; 45(3):713-20. PubMed ID: 11806723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 2',6'-dimethyl-L-tyrosine-containing pyrazinone opioid mimetic mu-agonists with potent antinociceptive activity in mice.
    Jinsmaa Y; Okada Y; Tsuda Y; Shiotani K; Sasaki Y; Ambo A; Bryant SD; Lazarus LH
    J Pharmacol Exp Ther; 2004 Apr; 309(1):432-8. PubMed ID: 14718580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism.
    Salvadori S; Guerrini R; Balboni G; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
    J Med Chem; 1999 Dec; 42(24):5010-9. PubMed ID: 10585210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism.
    Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH
    J Med Chem; 2004 Jul; 47(16):4066-71. PubMed ID: 15267245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
    Li T; Fujita Y; Shiotani K; Miyazaki A; Tsuda Y; Ambo A; Sasaki Y; Jinsmaa Y; Marczak E; Bryant SD; Salvadori S; Lazarus LH; Okada Y
    J Med Chem; 2005 Dec; 48(25):8035-44. PubMed ID: 16335927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
    Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
    J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.
    Schiller PW; Fundytus ME; Merovitz L; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Coderre TJ
    J Med Chem; 1999 Sep; 42(18):3520-6. PubMed ID: 10479285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the structure-activity relationship of 2',6'-dimethyl-l-tyrosine (Dmt) derivatives: bioactivity profile of H-Dmt-NH-CH(3).
    Fujita Y; Tsuda Y; Motoyama T; Li T; Miyazaki A; Yokoi T; Sasaki Y; Ambo A; Niizuma H; Jinsmaa Y; Bryant SD; Lazarus LH; Okada Y
    Bioorg Med Chem Lett; 2005 Feb; 15(3):599-602. PubMed ID: 15664820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2).
    Fichna J; do-Rego JC; Chung NN; Lemieux C; Schiller PW; Poels J; Broeck JV; Costentin J; Janecka A
    J Med Chem; 2007 Feb; 50(3):512-20. PubMed ID: 17266203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties.
    Fujita Y; Tsuda Y; Li T; Motoyama T; Takahashi M; Shimizu Y; Yokoi T; Sasaki Y; Ambo A; Kita A; Jinsmaa Y; Bryant SD; Lazarus LH; Okada Y
    J Med Chem; 2004 Jul; 47(14):3591-9. PubMed ID: 15214786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bioavailability of a new class of micro-opioid receptor agonists containing 3,6-bis[Dmt-NH(CH(2))(n)]-2(1H)-pyrazinone with central-mediated analgesia.
    Jinsmaa Y; Miyazaki A; Fujita Y; Li T; Fujisawa Y; Shiotani K; Tsuda Y; Yokoi T; Ambo A; Sasaki Y; Bryant SD; Lazarus LH; Okada Y
    J Med Chem; 2004 May; 47(10):2599-610. PubMed ID: 15115401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique high-affinity synthetic mu-opioid receptor agonists with central- and systemic-mediated analgesia.
    Okada Y; Tsuda Y; Fujita Y; Yokoi T; Sasaki Y; Ambo A; Konishi R; Nagata M; Salvadori S; Jinsmaa Y; Bryant SD; Lazarus LH
    J Med Chem; 2003 Jul; 46(15):3201-9. PubMed ID: 12852751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of opioidmimetics, 3-[H-Dmt-NH(CH(2))(m)]-6-[H-Dmt-NH(CH(2))(n)]-2(1H)-pyrazinones, and studies on structure-activity relationships.
    Shiotani K; Miyazaki A; Li T; Tsuda Y; Yokoi T; Ambo A; Sasaki Y; Bryant SD; Jinsmaa Y; Lazarus LH; Okada Y
    Med Chem; 2007 Nov; 3(6):583-98. PubMed ID: 18045209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
    Li T; Shiotani K; Miyazaki A; Tsuda Y; Ambo A; Sasaki Y; Jinsmaa Y; Marczak E; Bryant SD; Lazarus LH; Okada Y
    J Med Chem; 2007 Jun; 50(12):2753-66. PubMed ID: 17497839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R' analogues: acquisition of potent delta antagonism.
    Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH
    Bioorg Med Chem; 2003 Dec; 11(24):5435-41. PubMed ID: 14642588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH.
    Balboni G; Cocco MT; Salvadori S; Romagnoli R; Sasaki Y; Okada Y; Bryant SD; Jinsmaa Y; Lazarus LH
    J Med Chem; 2005 Aug; 48(17):5608-11. PubMed ID: 16107162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [N-allyl-Dmt1]-endomorphins are micro-opioid receptor antagonists lacking inverse agonist properties.
    Marczak ED; Jinsmaa Y; Li T; Bryant SD; Tsuda Y; Okada Y; Lazarus LH
    J Pharmacol Exp Ther; 2007 Oct; 323(1):374-80. PubMed ID: 17626793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1).
    Balboni G; Guerrini R; Salvadori S; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH
    J Med Chem; 2005 Dec; 48(26):8112-4. PubMed ID: 16366592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2.
    Li T; Fujita Y; Tsuda Y; Miyazaki A; Ambo A; Sasaki Y; Jinsmaa Y; Bryant SD; Lazarus LH; Okada Y
    J Med Chem; 2005 Jan; 48(2):586-92. PubMed ID: 15658871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.